Yasuhito Arai
Senior researcher
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (10)
Year:
2026
Year:
2026
Tyrosine kinase inhibitors are initially efficacious against anaplastic lymphoma kinase (ALK) fusion gene–positive lung adenocarcinoma, but acquired resistance inevitably occurs. Therefore, alternative treatment strategies are needed for tyrosine kinase inhibitor–resistant cases. Although the use of immune checkpoint inhibitors (ICI) has improved the prognosis of patients with lung cancer, patients with ALK+ lung adenocarcinoma exhibit little or no response to immunotherapy and the underlying resistance mechanisms remain unknown. In this study, we explored the immunologic status of the tumor microenvironment (TME) in ALK+ lung adenocarcinoma tissues. Tumor-infiltrating leukocyte analysis revealed reduced numbers of effector T cells and increased myeloid-derived suppressor cells (MDSC) relative to ALK− lung adenocarcinoma cases, indicating that ALK+ lung adenocarcinoma has a myeloid cell–dominant immunosuppressive TME. Single-cell RNA sequencing analysis identified a subset of macrophages that expressed most T cell–attractant chemokines (CXCL9, CXCL10, and CXCL11), and the macrophages were inactivated in ALK+ lung adenocarcinoma. In contrast, ALK+ lung adenocarcinoma expressed high levels of MDSC-attractant chemokines (CXCL1 and CXCL8). In addition, ALK+ lung adenocarcinoma showed higher levels of IL6, an MDSC-inducing cytokine, than ALK– lung adenocarcinoma. An IL6R inhibitor transformed the TME in a murine ALK+ lung adenocarcinoma model, shifting it from an immunosuppressive to a T cell–dominant status. Although ICI monotherapy lacked antitumor effects, a combination of ICI and the IL6R inhibitor had significant antitumor effects in mice. Our findings illustrate the molecular basis of fusion gene–mediated immunosuppressive TMEs, providing a rationale for a novel combination immunotherapy for ALK+ lung adenocarcinoma. See related Spotlight by Vitale and Bria, p.1326
Year:
2025
Tyrosine kinase inhibitors are initially efficacious against anaplastic lymphoma kinase ( ALK ) fusion gene–positive lung adenocarcinoma, but acquired resistance inevitably occurs. Therefore, alternative treatment strategies are needed for tyrosine kinase inhibitor–resistant cases. Although the use of immune checkpoint inhibitors (ICI) has improved the prognosis of patients with lung cancer, patients with AL K + lung adenocarcinoma exhibit little or no response to immunotherapy and the underlying resistance mechanisms remain unknown. In this study, we explored the immunologic status of the tumor microenvironment (TME) in ALK + lung adenocarcinoma tissues. Tumor-infiltrating leukocyte analysis revealed reduced numbers of effector T cells and increased myeloid-derived suppressor cells (MDSC) relative to ALK − lung adenocarcinoma cases, indicating that ALK + lung adenocarcinoma has a myeloid cell–dominant immunosuppressive TME. Single-cell RNA sequencing analysis identified a subset of macrophages that expressed most T cell–attractant chemokines ( CXCL9 , CXCL10 , and CXCL11 ), and the macrophages were inactivated in ALK + lung adenocarcinoma. In contrast, ALK + lung adenocarcinoma expressed high levels of MDSC-attractant chemokines ( CXCL1 and CXCL8 ). In addition, ALK + lung adenocarcinoma showed higher levels of IL6, an MDSC-inducing cytokine, than ALK – lung adenocarcinoma. An IL6R inhibitor transformed the TME in a murine ALK + lung adenocarcinoma model, shifting it from an immunosuppressive to a T cell–dominant status. Although ICI monotherapy lacked antitumor effects, a combination of ICI and the IL6R inhibitor had significant antitumor effects in mice. Our findings illustrate the molecular basis of fusion gene–mediated immunosuppressive TMEs, providing a rationale for a novel combination immunotherapy for ALK + lung adenocarcinoma. See related Spotlight by Vitale and Bria, p.1326
Year:
2025
The recent rapid increase in colorectal cancer (CRC) cases, particularly among young patients, poses a significant public health concern in Japan and other countries. The association between the gut microbiota and CRC has been well established. Here, we present a detailed analysis of this association by combining whole-genome sequencing (WGS) and whole-transcriptome data from CRC tissues with whole-genome metagenomic sequencing (WGMS) of fecal samples. The utilization of explanatory artificial intelligence analysis enabled classification of the disease into four distinct subtypes. This microbiome-based subclassification was found to be correlated with specific clinical and molecular characteristics, and included a subgroup having a higher proportion of younger patients with an unfavorable prognosis. The WGS analysis revealed mutational signatures (SBS88 and ID18) associated with colibactin exposure; these were considered early clonal events and found in 70.3% of patients (97 out of 138), with higher prevalence in the younger subtype. APC hotspot mutation and frameshift deletion, which matched the colibactin signature and the colibactin-specific motif, were observed in 12 patients (8.7%). CRCs exhibiting colibactin-associated mutational signatures were more common in younger patients and had an immunosuppressive microenvironment. Colibactin exposure is a highly prevalent but modifiable risk factor for CRC in the Japanese population.
Year:
2024
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Collaborators (11)
Akiyoshi Hirayama
Keio University
Junji Koya
Senior Staff Scientist
National Cancer Center Research Institute
Yae Kanai
Keio University School of Medicine
Kouichi Ozaki
Visittng Professor
National Center for Geriatrics and Gerontology
Keisuke Kataoka
Chief
National Cancer Center Research Institute
Haruna Takeda
Laboratory head
-
Kazunori Aoki
Chief
National Cancer Center Research Institute
Tomoyoshi Soga
Keio University
Koji Okamoto
Professor
Teikyo University
Yuki Saito
National Cancer Center Research Institute
Shinichi Yachida
Professor
Osaka University
Make your next move.
Prepare your application
Review drafts before you send them.